Le Lézard
Classified in: Health, Science and technology
Subject: TRI

Hansa Biopharm announces positive high-level data from investigator-initiated phase 2 trial with imlifidase to treat anti-GBM disease


LUND, Sweden, Sept. 24, 2020 /PRNewswire/ -- Hansa Biopharma ("Hansa"), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announces positive high-level data from an investigator-initiated phase 2 trial that evaluated safety, tolerability and efficacy of imlifidase in 15 patients with severe anti-GBM antibody disease.

Anti-GBM antibody disease, also known as Goodpasture's disease, is a severe autoimmune disease where the immune system mistakenly develops IgG-antibodies directed against the glomerular basement membrane (GBM), resulting in an acute immune attack causing severe kidney injury and, in some patients, also injuring the lungs.

Anti-GBM is a rare and acute immunological disease with a significant unmet medical need that affects approximately 1.5 in a million people annually, with a majority of patients losing their kidney function and requiring chronic dialysis and kidney transplantation. In severe cases, anti-GBM antibody disease may lead to death.

The first high-level data read out has been completed and the encouraging results indicate that imlifidase treatment may lead to increased renal survival in patients with anti-GBM antibody disease due to rapid clearance of IgG antibodies. The phase 2 anti-GBM study enrolled 15 subjects, six females and nine males with a median age of 61 years of age (range 19-79 years) recruited across centers from five European countries, including Sweden, Denmark, Czech Republic, France and Austria.

At inclusion, ten of the patients were dialysis dependent, including five that were oliguric/anuric, while five patients were dialysis independent but had eGFR levels below 15 ml/min. Six hours after imflidase no patient had anti-GBM antibody levels above the normal range.

At six months, ten patients were dialysis independent (median eGFR 27 ml/min). Four patients were dialysis dependent, while one patient had died (unrelated to imlifidase treatment). The safety profile of imlifidase in the population was concluded as being favourable.

"The positive results from the phase 2 trial suggest the potential for treatment and thereby the opportunity to increase the chances of renal survival in difficult to treat patients with anti-GBM disease", says Sponsor and Coordinating Principle Investigator, Mårten Segelmark, Professor of Nephrology at Lund University and Linköping University.

"We are very encouraged by the positive outcome from the phase 2 trial in anti-GBM antibody disease. Anti-GBM is the first IgG-mediated disease outside transplantation, where imlifidase has been shown to stop an immunologic attack. This marks an important milestone in Hansa Biopharma's efforts to develop potentially lifesaving and life altering therapies for patients with rare immunological diseases within a range of therapeutic areas where there is a significant unmet medical need", says Søren Tulstrup, President and CEO, Hansa Biopharma.

Hansa Biopharma was granted orphan drug designation for imlifidase as a treatment for anti-GBM antibody disease in both the EU and the US in 2018.

Hansa Biopharma is hosting a Capital Markets Day planned for October 29, 2020 in Copenhagen, where more information from the anti-GBM phase 2 trial will be presented. For more information and registration for this event, click here.

This is information that Hansa Biopharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through th the contact person set out above at 20:15 CET on September 24, 2020.

CONTACT:

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com

Katja Margell
Head of Corporate Communications 
Hansa Biopharma 
Mobile: +46 (0) 768-198 326
E-mail: katja.margell@hansabiopharma.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharm-announces-positive-high-level-data-from-investigator-initiated-phase-2-trial-with-iml,c3202826

The following files are available for download:

https://mb.cision.com/Main/1219/3202826/1310647.pdf

Release

SOURCE Hansa Biopharma AB


These press releases may also interest you

23 oct 2020
The liquid biopsy market is poised to grow by USD 4.02 billion during 2020-2024, progressing at a CAGR of almost 38% during the forecast period. The report on the liquid biopsy market provides a holistic update, market size and forecast, trends,...

23 oct 2020
The dPCR market is poised to grow by USD 518.69 million during 2020-2024, progressing at a CAGR of over 24% during the forecast period. The report on the dPCR market provides a holistic update, market size and forecast, trends, growth drivers, and...

23 oct 2020
Emerging leader in infused cannabis beverages BevCanna Enterprises Inc. announced today that the Company has received a capital injection of $750,000. The funds are the proceeds of a Unit private placement (the "Private...

23 oct 2020
The food recall warning issued on October 22, 2020 has been updated to include additional product information. This additional information was identified during the Canadian Food Inspection Agency's (CFIA) food safety investigation. Nature's Intent...

23 oct 2020
The Washington State Department of Health issued Eden Home Health of Spokane County, LLC a Certificate of Need to provide Home Health Care services in Spokane County on December 24, 2019.  Effective July 28, 2020, Eden Home Health of Spokane County,...

23 oct 2020
As someone who has spent a good portion of the last 20 years in scrubs, I definitely have my opinions on what I like and dislike! Comfort, pockets, and non-iron are my priorities. I also know that my coworkers have some strong feelings about their...



News published on 24 september 2020 at 14:24 and distributed by: